The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1173
January 5, 2004
View Complete Issue         Table of Contents 2019 
Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia
January 5, 2004 (Issue: 1173)
Alfuzosin hydrochloride (Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since 1987. Alpha1-blockers cause relaxation of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia
Article code: 1173a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.